MBX Biosciences, Inc. (MBX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
MBX Biosciences, Inc. - Special Call
MBX Biosciences, Inc. - Special Call Company Participants Jim DeNike Peter Hawryluk - CEO, President & Director Salomon Azoulay - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Trevor Allred - Oppenheimer & Co. Inc., Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Presentation Operator Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded.
Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet
The mean of analysts' price targets for MBX Biosciences, Inc. (MBX) points to an 88.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market
MBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and could rival Yorvipath, the only approved therapy, with the added advantage of once-weekly dosing. MBX's pipeline includes early-stage GLP-1 assets targeting post-bariatric hypoglycemia and obesity, supported by a solid cash position into mid-2027.
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy
MBX Biosciences offers a unique prodrug approach with three promising candidates targeting hypoparathyroidism, post-bariatric hypoglycemia, and obesity - two of its three drug candidates are GLP receptor agonists. Upcoming Phase 2 data for canvuparatide in hypoparathyroidism is a major near-term catalyst, with limited competition and potential for multi-billion dollar peak sales. Despite early-stage risks, MBX's strong management, solid cash position, and differentiated pipeline make it a more attractive value proposition than many GLP-1 peers.
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering.
